

Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals

Willem A. Mak¹, Wendy Visser¹, Marijke van der Vliet¹, Hilde Y. Markus¹, Johannes G.M. Koeleman¹, and David Ong¹

¹Franciscus Gasthuis en Vlietland

May 2, 2023

Abstract

COVID-19 bivalent ancestral/Omicron mRNA booster vaccinations became available to boost and expand the immunity against SARS-CoV-2 Omicron infections. In a prospective cohort study including 59 healthcare workers, we assessed SARS-CoV-2 ancestral and Omicron BA.5-specific neutralizing antibody and T cell responses in previously infected and infection-naive individuals. Also, we assessed the effect of an ancestral/Omicron BA.1 bivalent mRNA booster vaccination on these immune responses. 10 months after previous monovalent mRNA vaccinations, ancestral SARS-CoV-2 S1-specific T cell and anti-RBD IgG responses remained detectable in most individuals and a previous SARS-CoV-2 infection was associated with increased T cell responses. T cell responses, anti-RBD IgG, and Omicron BA.5 neutralization activity increased after receiving an ancestral/Omicron BA.1 bivalent booster mRNA vaccination. An Omicron BA.5 infection in addition to bivalent vaccination led to a higher ratio of Omicron BA.5 to ancestral strain neutralization activity compared to bivalent vaccination without a recent SARS-CoV-2 infection. In conclusion, SARS-CoV-2 T cell and antibody responses persist for up to 10 months after a monovalent booster mRNA vaccination. An ancestral/Omicron BA.1 bivalent booster mRNA vaccination increases these immune responses and also induces Omicron BA.5 cross-neutralization antibody activity. Finally, our data indicate that hybrid immunity is associated with improved preservation of T cell immunity.

Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals

Willem A. Mak ¹ (ashwinmak98@gmail.com)

Wendy Visser ¹ (wwendy.visser@gmail.com)

Marijke van der Vliet ¹ (m.vandervliet@franciscus.nl)

Hilde Y. Markus ¹ (hildemarkus@gmail.com)

Johannes G.M. Koeleman ¹ (h.koeleman@franciscus.nl)

David S.Y. Ong ^{1,2 *}

^a Department of Medical Microbiology and Infection Control, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands

^b Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

*** Corresponding author:** David S.Y. Ong, MD, PhD, PharmD, MSc

Email: davidsyong@gmail.com

Tel.: +31 10 461 6076

Kleiweg 500, 3045PM Rotterdam, The Netherlands

Word count: 2500

Keywords: Omicron, SARS-CoV-2, COVID-19, antibodies, T cells, vaccination

Abstract

COVID-19 bivalent ancestral/Omicron mRNA booster vaccinations became available to boost and expand the immunity against SARS-CoV-2 Omicron infections. In a prospective cohort study including 59 health-care workers, we assessed SARS-CoV-2 ancestral and Omicron BA.5-specific neutralizing antibody and T cell responses in previously infected and infection-naïve individuals. Also, we assessed the effect of an ancestral/Omicron BA.1 bivalent mRNA booster vaccination on these immune responses. 10 months after previous monovalent mRNA vaccinations, ancestral SARS-CoV-2 S1-specific T cell and anti-RBD IgG responses remained detectable in most individuals and a previous SARS-CoV-2 infection was associated with increased T cell responses. T cell responses, anti-RBD IgG, and Omicron BA.5 neutralization activity increased after receiving an ancestral/Omicron BA.1 bivalent booster mRNA vaccination. An Omicron BA.5 infection in addition to bivalent vaccination led to a higher ratio of Omicron BA.5 to ancestral strain neutralization activity compared to bivalent vaccination without a recent SARS-CoV-2 infection. In conclusion, SARS-CoV-2 T cell and antibody responses persist for up to 10 months after a monovalent booster mRNA vaccination. An ancestral/Omicron BA.1 bivalent booster mRNA vaccination increases these immune responses and also induces Omicron BA.5 cross-neutralization antibody activity. Finally, our data indicate that hybrid immunity is associated with improved preservation of T cell immunity.

Introduction

Shortly after the first detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant in November 2021, Omicron became the global dominant variant that sustains the ongoing coronavirus disease 2019 (COVID-19) pandemic.^{1,2} Omicron infections are mainly restricted to the upper respiratory tract and are thus generally associated with mild disease.^{3,4} However, Omicron infections may still result in severe disease in immunocompromized patients or those with pre-existing comorbidities, which substantially contributes to hospitalization rates and general disease burden.^{5,6}

Several observational studies reported a high incidence of Omicron vaccine-breakthrough infections and reinfections.^{7,8} These findings can be explained by the more than 30 substitutions in the spike protein, which make Omicron highly transmissible and very efficient at immune evasion.^{9,10} Moreover, these characteristics improved even further in each Omicron subvariant, including the previously dominant BA.1, BA.2, BA.4, and BA.5,^{1,10} and the most recent dominant subvariants XBB and XBB1.5.^{2,11}

The continuing emergence of new Omicron subvariants and concerns about waning immunity have led to the development of bivalent booster vaccines. From September 2022, these bivalent vaccines, containing spike-encoding mRNA of both the ancestral strain and Omicron BA.1, were first administered. However, a limited number of studies explored the effects of these bivalent vaccinations and latest Omicron variant infections on both neutralizing antibody (nAb) and T cell responses. Therefore, we performed a prospective cohort study aimed to investigate the impact of an ancestral/Omicron BA.1 bivalent booster vaccination, a recent Omicron BA.5 infection, or a combination of these on ancestral and Omicron BA.5 specific T cell and nAbs responses.

Methods

Study design

The study population consisted of 59 healthcare workers (HCWs) who had received their primary vaccinations and were part of our ongoing prospective cohort as described previously.¹² Whole blood was collected at two timepoints: September/October 2022 (T1) and December 2022 (T2). In between these timepoints the majority of HCWs received an ancestral/Omicron BA.1 bivalent booster vaccination. Blood samples were collected in heparin tubes via venipuncture and were processed as described previously.¹³ This study received approval from the Medical Research Ethical Committee United (protocol number R20.030) and was performed according to the Declaration of Helsinki as revised in 2013.

SARS-CoV-2 S1 IFN- γ ELISpot

Interferon-gamma (IFN- γ) T cell responses after stimulation with spike protein subunit 1 (S1) and nucleocapsid (N) peptides were assessed using the T-spot®.COVID (Oxford Immunotec, UK) kit as described previously.¹³

SARS-CoV-2 Omicron BA.5 IFN- γ ELISpot

An in-house-developed ELISpot was applied to detect IFN- γ T cell responses against Omicron BA.5 spike peptides. On day 1, polyvinylidene fluoride membranes precoated with a monoclonal anti-IFN- γ antibody (mAb 1-D1K, Mabtech, Sweden) were washed thrice with phosphate-buffered saline (PBS) and were conditioned with AIM-V (AIM-V® + AlbuMAX® (BSA); Gibco, USA) for 30 min at room temperature. The following stimulations were separately added, each in a volume of 50 μ L per well: AIM-V medium as negative control, anti-CD3 (1:1000, mAb CD3-2, Mabtech) as positive control, Omicron BA.5 mutation peptides, and corresponding ancestral strain peptides (PepTivator® SARS-CoV-2 Prot_S B.1.1.529/BA.5, Miltenyi Biotec, Germany). These peptide pools consisted of 15-mer peptides with 11 amino acids overlap and were added to a final 0.66 μ g/mL concentration. An amount of 2.5×10^5 PBMCs in 100 μ L AIM-V was added to each well, whereafter the microtiter plate was incubated for 16–20 h at 37°C with 5% CO₂ in a humidified atmosphere. On day 2, the PBMCs were washed off the plate with PBS, and 100 μ L alkaline phosphatase-conjugated antibody (1:200, 7-B6-1-ALP, Mabtech) was added and incubated for two hours at room temperature. Subsequently, the microtiter plate was washed with PBS and 100 μ L substrate (BCIP-NBT-plus; Mabtech) was added and incubated at room temperature for 7–12 min, after which the reaction was stopped with demineralized water.

ELISpot Image Processing and Spot Quantification

For the spot quantification, we used the method previously described.¹⁴ In short, images of the ELISpot membranes were made with the Dx1 microscope (Veho, UK) using Plugable Digital Viewer v3.1.07 for Windows and an intensity threshold of 95 was applied instead of the previously described threshold of 75 to enhance spot detection sensitivity. The number of spots in the negative control was subtracted from the number of spots in peptide-stimulated conditions for each individual sample. Samples were excluded if the positive control resulted in less than 20 spots.

SARS-CoV-2 Anti-RBD IgG Quantitative ELISA

The anti-RBD (ancestral strain) IgG serum concentrations were determined using a quantitative enzyme-linked immunosorbent assay (ELISA) (Beijing Wantai Biological Pharmacy Enterprise, China) as described previously.¹³

SARS-CoV-2 ancestral and Omicron BA.5 sVNT

Surrogate virus neutralization tests (sVNT) were performed to assess the neutralizing activity of serum anti-RBD antibodies. The neutralizing activity against the ancestral strain RBD was determined using the kit (Genscript Biotech, US) and protocol as previously described.¹⁵ A second sVNT kit (ACROBiosystems, US) was used to determine the neutralizing activity of serum antibodies against the Omicron BA.5 RBD. The sVNT was performed according to the manufacturer's guidelines using a fully automatic ETI-MAX (Diasorin, Italy) system. Serum samples, as well as the positive and negative control, were diluted 1:9 with a dilution buffer. These dilutions were added 1:1 to RBD-horseradish peroxidase (HRP-RBD) in a pre-coated

well, whereafter this was incubated for 1 hour at 37°C. After washing the wells with a washing buffer, a substrate solution was added and incubated for 20 min at 37°C. Lastly, a stop solution was added and the absorbance was measured at 450 nm and 620 nm to reduce background noise. The neutralizing activity was calculated as the percentage of inhibition using the following formula: $Inhibition (\%) = (1 - (OD_{450nm} - OD_{620nm})) \times 100$.

Statistical analyses

All data obtained in this study were expressed as median with interquartile range (IQR) and statistical analyses were performed using GraphPad Prism v9 (GraphPad Software). The Wilcoxon signed-rank test was applied to compare paired datasets and the Mann–Whitney U test was applied to compare two independent data sets. The Kruskal–Wallis test with Dunn’s multiple comparison test was performed to compare three or more independent groups. All statistical tests were performed at a two-tailed α -level of 0.05.

Results

SARS-CoV-2-specific T cell and antibody responses in prior-infected and infection-naive individuals 10 months after previous monovalent mRNA vaccinations

First, we investigated whether a prior SARS-CoV-2 infection in addition to primary and booster vaccinations results in prolonged increased SARS-CoV-2-specific T cell and antibody responses. Therefore, we determined these immune responses in HCWs who tested SARS-CoV-2 PCR positive more than three months ago (previous) or within three months (recent) and in HCWs who never tested SARS-CoV-2 positive (naive) until the time of blood collection. All HCWs had received mRNA or viral vector COVID-19 primary vaccinations, and HCWs received no (n=4), one (n=40), or two (n=7) booster mRNA vaccinations. The last vaccination was received at median 307 (IQR 301-314.5) days before the first blood collection in this study. Here, we observed higher spike S1-specific T cell responses in previously infected HCWs than in infection-naive HCWs ($p = 0.0351$), whereas responses were comparable between the recently infected and infection-naive HCWs (**Fig. 1A**). Nucleocapsid protein (N)-specific T cell responses were only observed in prior infected HCWs since immunological responses against the N protein are not elicited by mRNA vaccines (**Fig. 1B**).

For the humoral immunity component, anti-SARS-CoV-2-RBD IgG (of ancestral virus) was detectable in all HCWs and the serum concentrations were comparable between all groups (**Fig. 1C**). Also, we investigated the neutralizing activity of serum antibodies against Omicron BA.5 spike-RBD (**Fig. 1D**). According to the manufacturer’s cut-off value of [?]20% inhibition, 83.3% of previously infected, 76.9% of recently infected, and 38.5% of infection-naive HCWs were considered positive for the presence of Omicron BA.5 nAbs. We observed considerable intragroup variations, but no significant differences between the groups.




Fig. 1. SARS-CoV-2-specific immune responses in vaccinated HCWs 10 months after previous vaccinations. Each individual data point represents one previously infected (n=26), recently infected (n=12), or infection-naive (n=13) HCW. T cell responses against SARS-CoV-2(A) spike S1 and (B) nucleocapsid protein.(C) Total serum anti-SARS-CoV-2 RBD (ancestral strain) IgG concentrations. (D) Serum antibody neutralizing

activity against Omicron BA.5 spike RBD presented as percentage inhibition. Data are represented as median with IQR and were assessed by a Kruskal-Wallis test with Dunn's post-hoc analysis.

The effect of a bivalent ancestral/Omicron BA.1 COVID-19 booster mRNA vaccination on SARS-CoV-2-specific immune responses

After pooling the previously infected, recently infected and infection-naïve HCWs, 18 HCWs received a COVID-19 bivalent booster mRNA vaccination, i.e., Comirnaty Original/Omicron BA.1 (n=13) or Spikevax bivalent Original/Omicron BA.1 (n=5), in between T1 and T2. Accordingly, we determined the effect of a bivalent booster vaccination, which contains spike-encoding mRNA of both the SARS-CoV-2 ancestral strain and Omicron BA.1, on T cell and antibody responses. We observed a considerable increase in S1-specific T cell responses ($p = 0.0004$), anti-RBD (ancestral) IgG antibodies ($p = 0.0090$), and Omicron BA.5 serum neutralization activity ($p = 0.0023$) after bivalent booster vaccination (Fig. 2A-C). Furthermore, we also assessed the immune responses of 8 HCWs who were not vaccinated in between the two timepoints with an interval of 70 (69.5-75.5) days. These HCWs showed comparable immune responses at both timepoints (Fig. 2D-F).




Fig. 2. SARS-CoV-2-specific immune responses before and after bivalent booster vaccination. (A-C) Blood was collected from 18 HCWs 11 (IQR 5-31) days before (T1) and 57 (IQR 38-65) days after (T2) bivalent booster vaccination with 70 (IQR 69-71) days in between the two timepoints. (D-F) Immune responses of 8 HCWs who received no bivalent booster vaccination were also assessed at similar time points with an interval of 70 (IQR 69.5-75.5) days. (A,D) Spike S1-specific T cell responses. (B,E) Anti-RBD (ancestral) IgG concentrations. (C,F) Omicron BA.5 serum neutralization activity. HCWs were excluded if a previous (booster) vaccination was received within three months before T1 or if the HCW tested SARS-CoV-2 RT-qPCR positive in between T1 and T2. Data are represented as median with IQR and were assessed by a Wilcoxon signed-rank test.

Ratio of Omicron BA.5 to ancestral SARS-CoV-2 strain-specific immunological responses after Omicron BA.5 infection and ancestral/Omicron BA.1 bivalent vaccination

We determined the effect of a recent Omicron BA.5 infection, an ancestral/Omicron BA.1 bivalent booster vaccination, and both on Omicron BA.5 and ancestral SARS-CoV-2 specific immunity. For this purpose, we stimulated PBMCs with solely Omicron BA.5 mutation peptides and the corresponding ancestral strain spike peptides. Also, we performed sVNT assays using either Omicron BA.5 or ancestral SARS-CoV-2 pseudovirus particles.

At T1, the T cell responses against these specific peptides were overall low, and the Omicron BA.5/ancestral ratios were comparable between the two groups (**Fig. 3A and Supplementary Fig. 2A**). The neutralization activity was not significantly different between the two groups at T1 (**Figure 3B**). However, 92% of recently infected HCWs versus 57% of non-recently infected HCWs exhibited higher (i.e., a ratio of >1) neutralization activity against Omicron BA.5 compared to the ancestral strain.

At T2, T cell responses were also overall low and only the HCWs who were both recently infected with Omicron BA.5 and received a bivalent booster vaccination had 2.2-fold higher T cell responses against Omicron BA.5 than against ancestral strain (**Figure 3C and Supplementary Fig. 2C**). Strikingly, this HCW group also demonstrated a 2.4-fold higher neutralizing activity against Omicron BA.5 compared to ancestral strain, which was higher ($p = 0.0456$) than in HCWs who received a bivalent vaccination but without a recent Omicron BA.5 infection (**Fig. 3D**). The latter group exhibited a 1.4-fold higher neutralization activity.

For comparison, we also assessed the Omicron BA.5/ancestral neutralization ratios in pre-Omicron BA.5 serum samples which were obtained before and after monovalent booster vaccination in 2021.¹² Accordingly, we observed that there was an overall higher neutralizing activity of the ancestral strain than of BA.5 (**Supplementary Fig. 2**).

Hosted file

image3.emf available at <https://authorea.com/users/613790/articles/640965-ancestral-sars-cov-2-and-omicron-ba-5-specific-neutralizing-antibody-and-t-cell-responses-after-omicron-bivalent-booster-vaccination-in-previously-infected-and-infection-naive-individuals>

Fig. 3. SARS-CoV-2 Omicron BA.5/ancestral specific T cell response and antibody neutralization ratios. Individual data points comprise the ratio of Omicron BA.5 to ancestral (**A, C**) T cell responses or (**B, D**) serum neutralization activity. Recent Omicron BA.5 infection and bivalent booster vaccination are presented as positive (+) or negative (-). (**A-B**) At T1, HCWs were divided into two groups based on recent (i.e., <3 months) Omicron BA.5 infection. (**C-D**) At T2, HCWs were divided into four groups based on recent Omicron BA.5 infection and receiving a bivalent booster vaccination. Absolute values that were used to calculate these ratios are presented in **Supplementary Fig. 1A-D**. Data are represented as median with IQR and were assessed by a (**A-B**) Mann-Whitney U test or (**C-D**) Kruskal-Wallis test with Dunn's post hoc analysis.

Discussion

This study showed that approximately 10 months after receiving the last monovalent (booster) mRNA vaccination, ancestral SARS-CoV-RBD IgG antibodies were present and a previous SARS-CoV-2 infection in addition to vaccination led to higher T cell responses against SARS-CoV-2 S1. Subsequently, an ancestral/Omicron BA.1 bivalent booster vaccination significantly increased these T cell and antibody responses against SARS-CoV-2, including serum antibody neutralization activity against Omicron BA.5. Irrespective of bivalent booster vaccination, a recent Omicron BA.5 infection increased the ratio of Omicron BA.5 to ancestral strain neutralization activity.

nAbs are considered the first line of defense within adaptive immunity against viruses as these bind external viral epitopes and thereby prevent infection of host cells. After infection both the nAbs and T cells contribute

to limiting viral replication and preventing disease progression.¹⁶ In our previous study, we similarly assessed anti-RDB IgG antibody and S1-specific T cell responses up to seven months post (booster) vaccinations and observed higher anti-RBD IgG concentrations in individuals with a previous or a recent infection in comparison to infection-naïve individuals.¹² In the period from seven to 10 months post vaccination, the infection-induced higher anti-RBD IgG levels seem to normalize towards infection-naïve levels. In this current study, a recent Omicron BA.5 infection was not associated with statistically significant higher anti-RBD concentrations, although the recently infected HCWs had 3-fold higher anti-RBD IgG median concentrations than infection-naïve HCWs. Nevertheless, all HCWs had detectable anti-RBD IgG antibodies, which is in line with other studies showing waning but yet sustained anti-RBD antibodies levels up to nine months after mRNA vaccinations.^{17–19}

Protection against reinfection is considered to be reduced against the Omicron variant in comparison to previous SARS-CoV-2 variants.²⁰ The proportion of HCWs who were considered positive for the presence of Omicron BA.5 nAbs was increased in both prior-infected groups, and inhibition activity was substantially higher in the recently Omicron BA.5 infected individuals. In addition, a recent Omicron BA.5 infection in combination with a bivalent vaccination led to an increased ratio of Omicron BA.5 to ancestral strain neutralization activity. Moreover, Omicron BA.5 partially escapes nAbs induced by Omicron BA.1 vaccination, indicating that vaccine-induced Omicron BA.1-specific nAbs might not optimally neutralize Omicron BA.5.^{21,22} Nevertheless, we observed significantly higher neutralization activity against Omicron BA.5 after Omicron BA.1 bivalent vaccination in comparison to no bivalent booster vaccination.

Infection plus vaccination, termed hybrid immunity, seemed to induce higher T cell responses against spike S1 than vaccination alone. Although the underlying mechanisms of hybrid immunity is not well understood, it is known that a combination of infection and vaccination induces more polyfunctional spike-specific T cells than infection or vaccination alone.^{23–25} In addition, a SARS-CoV-2 infection also induces T cell responses against non-spike proteins such as the nucleocapsid protein, allowing for a broader and more protective T cell response against the virus.²⁶ Notably, T cell responses were similar between the recently Omicron BA.5 infected and infection-naïve HCWs, which is potentially explained by the mild disease following Omicron BA.5 infection since mild COVID-19 elicits weak T cell responses.^{27,28}

CD4⁺ and CD8⁺ T cell epitopes in the spike protein remain largely preserved across SARS-CoV-2 variants, including Omicron BA.5.^{29–32} This possibly explains why we observed weak T cell responses against the Omicron BA.5 peptide pool that solely consists of mutation-containing peptides. However, broader T cell responses are likely to be cross-reactive against different variants, as T cells may prevent severe COVID-19 even in the absence of effective nAbs.³⁰

Although this study is one of the first to investigate both SARS-CoV-2 ancestral and Omicron BA.5 specific humoral and cellular immune responses after ancestral/Omicron BA.1 bivalent booster vaccination, there are some limitations to consider. First, some subgroups were limited in size, because only a small proportion of HCWs were recently infected or received a bivalent booster vaccination. Second, we assessed immune responses against Omicron BA.5, while the BA.5 sublineage BQ.1 and the BA.2 sublineage XBB1.5, became the global dominant variants as of December 2022 and March 2023, respectively.^{2,33} However, knowledge of Omicron BA.5-specific immunity is still relevant since a considerable number of epitopes remain conserved among Omicron subvariants, and BA.5 sublineages (such as BQ.1) may become more prevalent in the future.³²

In conclusion, SARS-CoV-2 specific nAb and T cell responses persist for up to at least 10 months after monovalent booster mRNA vaccinations, and hybrid immunity is associated with improved preservation of T cell immunity. An ancestral/Omicron BA.1 bivalent booster mRNA vaccination induces nAb and T cell responses against the ancestral strain and cross-protective neutralization activity against Omicron BA.5. Future studies must elucidate whether nAb and T cell responses induced by prior-infection and bivalent vaccinations are protective against new emerging subvariants.

Funding

The study received no funding.

CRediT authorship contribution statement

Willem A. Mak : Conceptualization, Data curation, Validation, Visualization, Formal analysis, Writing – original draft, Writing – review & editing. **Wendy Visser** : Investigation, Validation, Visualization, Formal analysis, Writing – review & editing. **Marijke van der Vliet** : Project administration, Writing – review & editing. **Hilde Y. Markus** : Investigation, Writing – review & editing. **Johannes G. M. Koeleman** : Conceptualization, Supervision, Writing – review & editing. **David S. Y. Ong** : Conceptualization, Validation, Visualization, Supervision, Writing –review & editing.

Acknowledgments

We thank our technicians Nicolette van Drunen, Joyce van Veen, Mariska van Wijk, and Frans Keuren for their assistance during the serological tests.

References

- 1 Xia Shuai, Wang Lijue, Zhu Yun, Lu Lu, Jiang Shibo. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. *Signal Transduct Target Ther* 2022;**7** (1):1–7. Doi: 10.1038/s41392-022-01105-9.
- 2 COVID-19 Weekly Epidemiological Update 135. *World Health Organization*, 2023.
- 3 Doll Margaret K., Waghmare Alpana, Heit Antje, Levenson Shakoor Brianna, Kimball Louise E., Ozbek Nina, et al. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves. *JAMA Netw Open* 2023;**6** (2):e231181. Doi: 10.1001/jamanetworkopen.2023.1181.
- 4 Looi Mun Keat. How are covid-19 symptoms changing? *BMJ* 2023;**380** :p3. Doi: 10.1136/bmj.p3.
- 5 Bahremand Taraneh, Yao Jiayun Angela, Mill Christopher, Piszczek Jolanta, Grant Jennifer M., Smolina Kate. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. *Lancet Reg Heal - Am* 2023;**20** (100461):1–8. Doi: 10.1016/j.lana.2023.100461.
- 6 Hyams Catherine, Challen Robert, Marlow Robin, Nguyen Jennifer, Begier Elizabeth, Southern Jo, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. *Lancet Reg Heal - Eur* 2023;**25** :1–11. Doi: 10.1016/j.lanepe.2022.100556.
- 7 Pulliam Juliet R.C., van Schalkwyk Cari, Govender Nevashan, von Gottberg Anne, Cohen Cheryl, Groome Michelle J., et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. *Science (80-)* 2022;**376** (6593):1–8. Doi: 10.1126/science.abn4947.
- 8 Goga Ameena, Bekker Linda Gail, Garrett Nigel, Reddy Tarylee, Yende-Zuma Nonhlanhla, Fairall Lara, et al. Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa. *Lancet* 2022;**400** (10348):269–71. Doi: 10.1016/S0140-6736(22)01190-4.
- 9 Magazine Nicholas, Zhang Tianyi, Wu Yingying, McGee Michael C., Veggiani Gianluca, Huang Weis-han. Mutations and Evolution of the SARS-CoV-2 Spike Protein. *Viruses* 2022;**14** (3):1–11. Doi: 10.3390/v14030640.
- 10 Carabelli Alessandro M., Peacock Thomas P., Thorne Lucy G., Harvey William T., Hughes Joseph, de Silva Thushan I., et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev Microbiol* 2023;**21** :162–77. Doi: 10.1038/s41579-022-00841-7.
- 11 Mahase Elisabeth. Covid-19: What do we know about XBB.1.5 and should we be worried? *BMJ* 2023;**380** (p153):1–2. Doi: 10.1136/bmj.p153.

- 12 Faas Michel R, Mak Willem A, Markus Hilde Y, Zwan Ellen M Van Der, Vliet Marijke Van Der, Koeleman Johannes G M, et al. Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. *Vaccines* 2022;**10** (2132).
- 13 Mak Willem A., Koeleman Johannes G.M., van der Vliet Marijke, Keuren Frans, Ong David S.Y. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. *J Infect* 2022;**84** (2):171–8. Doi: 10.1016/j.jinf.2021.12.003.
- 14 Mak Willem A, Koeleman Johannes G M, Ong David S Y. Development of an in-house SARS-CoV-2 interferon-gamma ELISpot and plate reader-free spot detection method. *J Virol Methods* 2022;**300** (114398):1–6. Doi: 10.1016/j.jviromet.2021.114398.
- 15 Ong David S.Y., Keuren Frans, van der Vliet Marijke, Boxma – de Klerk Bianca M., Koeleman Johannes G.M. SARS-CoV-2 antibody response dynamics and heterogeneous diagnostic performance of four serological tests and a neutralization test in symptomatic healthcare workers with non-severe COVID-19. *J Clin Virol* 2021;**141** (104904):1–3. Doi: 10.1016/j.jcv.2021.104904.
- 16 Barouch Dan H. Covid-19 Vaccines — Immunity, Variants, Boosters. *N Engl J Med* 2022;**387** (11):1011–20. Doi: 10.1056/nejmra2206573.
- 17 Takeuchi Junko S, Fukunaga Ami, Yamamoto Shohei, Tanaka Akihito, Matsuda Kouki, Kimura Moto, et al. SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. *Sci Rep* 2022;**12** (15447):1–9. Doi: 10.1038/s41598-022-19581-y.
- 18 Terpos Evangelos, Karalis Vangelis, Ntanasis-Stathopoulos Ioannis, Apostolakou Filia, Gumeni Sentiljana, Gavriatopoulou Maria, et al. Sustained but Declining Humoral Immunity against SARS-CoV-2 at 9 Months Postvaccination with BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. *HemaSphere* 2022;**6** (1):E677. Doi: 10.1097/HS9.0000000000000677.
- 19 Dieckhaus Kevin D., Kim Min Jung, Shen Jian Bing, Liang Tina S., Kleinberg Michael J., Siedlarz Kristen M., et al. SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination. *Vaccines* 2023;**11** (2). Doi: 10.3390/vaccines11020358.
- 20 COVID-19 Forecasting Team. Past SARS-CoV-2 Infection Protection Against Reinfection: A Systematic Review and Meta-Analysis. *Lancet* 2023;**6736** (22):1–11. Doi: 10.1016/S0140-6736(22)02465-5.
- 21 Tuekprakhon Aekkachai, Nutalai Rungtiwa, Djokaite-Guraliuc Aiste, Zhou Daming, Ginn Helen M., Selvaraj Muneeswaran, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell* 2022;**185** (14):2422-2433.e13. Doi: 10.1016/j.cell.2022.06.005.
- 22 Lyke Kirsten E., Atmar Robert L., Islas Clara Dominguez, Posavad Christine M., Szydlo Daniel, Paul Chourdury Rahul, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. *Cell Reports Med* 2022;**3** (7). Doi: 10.1016/j.xcrm.2022.100679.
- 23 Keeton Roanne, Tincho Marius B., Suzuki Akiko, Benede Ntombi, Ngomti Amkele, Baguma Richard, et al. Impact of SARS-CoV-2 exposure history on the T cell and IgG response. *Cell Reports Med* 2023;**4** (1):100898. Doi: 10.1016/j.xcrm.2022.100898.
- 24 Almendro-Vazquez Patricia, Chivite-Lacaba Marta, Utrero-Rico Alberto, Gonzalez-Cuadrado Cecilia, Laguna-Goya Rocio, Moreno-Batanero Miguel, et al. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. *Front Immunol* 2022;**13** (981350):1–11. Doi: 10.3389/fimmu.2022.981350.
- 25 Lozano-Ojalvo Daniel, Camara Carmen, Lopez-Granados Eduardo, Nozal Pilar, del Pino-Molina Lucia, Bravo-Gallego Luz Yadira, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals. *Cell Rep* 2021;**36** (109570):1–5. Doi: 10.1016/j.celrep.2021.109570.

- 26 Kundu Rhia, Narean Janakan Sam, Wang Lulu, Fenn Joseph, Pillay Timesh, Fernandez Nieves Derqui, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun* 2022;**13** (1):1–8. Doi: 10.1038/s41467-021-27674-x.
- 27 Wolter Nicole, Jassat Waasila, Walaza Sibongile, Welch Richard, Moultrie Harry, Groome Michelle J., et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. *Nat Commun* 2022;**13** (1):1–8. Doi: 10.1038/s41467-022-33614-0.
- 28 Swadling Leo, Maini Mala K. T cells in COVID-19 — united in diversity. *Nat Immunol* 2020;**21** (11):1307–8. Doi: 10.1038/s41590-020-0798-y.
- 29 GeurtsvanKessel Corine H., Geers Daryl, Schmitz Katharina S., Mykytyn Anna Z., Lamers Mart M., Bogers Susanne, et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. *Sci Immunol* 2022;**7** (69):1–12. Doi: 10.1126/sciimmunol.abo2202.
- 30 Jacobsen Henning, Cobos Jimenez Viviana, Sitaras Ioannis, Bar-Zeev Naor, Čičin-Šain Luka, Higdon Melissa M., et al. Post-vaccination T cell immunity to omicron. *Front Immunol* 2022;**13** (944713):1–8. Doi: 10.3389/fimmu.2022.944713.
- 31 Park Kyemyung, Choi Seung Jin, Shin Eui Cheol. Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2. *Immune Netw* 2022;**22** (4):8–10. Doi: 10.4110/in.2022.22.e29.
- 32 Choi Seong Jin, Kim Dong Uk, Noh Ji Yun, Kim Sangwoo, Park Su Hyung, Jeong Hye Won, et al. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. *Cell Mol Immunol* 2022;**19** (3):447–8. Doi: 10.1038/s41423-022-00838-5.
- 33 COVID-19 weekly epidemiological update 123. *World Health Organization* , 2022.